natgillin/translations-raw huggingface dataset:
On 22 December 2017 the Authority communicated to the applicant, the Member States and the Commission its conclusion on whether the active substance fenpicoxamid can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Agencija je 22. decembra 2017 vložniku, državam članicam in Komisiji poslala svoj sklep o tem, ali se pričakuje, da bo aktivna snov fenpikoksamid izpolnila merila za odobritev iz člena 4 Uredbe (ES) št. 1107/2009.
On 23 March 2018 the Commission presented to the Standing Committee on Plants, Animals, Food and Feed the review report for fenpicoxamid and a draft Regulation providing that fenpicoxamid is approved.
Komisija je 23. marca 2018 Stalnemu odboru za rastline, živali, hrano in krmo predložila poročilo o pregledu snovi fenpikoksamid in osnutek uredbe o odobritvi snovi fenpikoksamid.
It is therefore appropriate to approve fenpicoxamid.
Zato je primerno, da se fenpikoksamid odobri.
In accordance with Article 13(4) of Regulation (EC) No 1107/2009, the Annex to Commission Implementing Regulation (EU) No 540/2011 should be amended accordingly.
V skladu s členom 13(4) Uredbe (ES) št. 1107/2009 bi bilo treba ustrezno spremeniti Prilogo k Izvedbeni uredbi Komisije (EU) št. 540/2011.
The active substance fenpicoxamid, as specified in Annex I, is approved subject to the conditions laid down in that Annex.
Aktivna snov fenpikoksamid, kot je opredeljena v Prilogi I, je odobrena v skladu s pogoji iz navedene priloge.
Conclusion on the peer review of the pesticide risk assessment of the active substance fenpicoxamid (XDE-777).
Izvedbena uredba Komisije (EU) št. 540/2011 z dne 25. maja 2011 o izvajanju Uredbe (ES) št. 1107/2009 Evropskega parlamenta in Sveta glede seznama registriranih aktivnih snovi (UL L 153, 11.6.2011, str. 1).
EFSA Journal 2018;16(1):5146, 27 pp. https://doi.org/10.2903/j.efsa.2018.5146.
PRILOGA I
Commission Implementing Regulation (EU) No 540/2011 of 25 May 2011 implementing Regulation (EC) No 1107/2009 of the European Parliament and of the Council as regards the list of approved active substances (OJ L 153, 11.6.2011, p. 1).
Splošno ime, identifikacijska številka
Expiration of approval
fenpikoksamid
Fenpicoxamid
CAS: 517875-34-2
CAS No: 517875-34-2
št.
CIPAC No: 991
CIPAC: 991
11 October 2028
11. oktober 2028
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on fenpicoxamid, and in particular Appendices I and II thereto, shall be taken into account.
Za izvajanje enotnih načel iz člena 29(6) Uredbe (ES) št. 1107/2009 se upoštevajo ugotovitve iz poročila o pregledu snovi fenpikoksamid ter zlasti dodatkov I in II k poročilu.
the impact of processing on the consumer risk assessment,
vpliv predelave na oceno tveganja za potrošnika,
the technical specification of the active substance as manufactured (based on commercial scale production) and the compliance of the toxicity batches with the confirmed technical specification;
tehnični specifikaciji aktivne snovi, kot je proizvedena (na podlagi proizvodnje v komercialnem obsegu), in skladnosti serij za ugotavljanje toksičnosti s potrjeno tehnično specifikacijo,
the effect of water treatment processes on the nature of residues present in drinking water;
učinku postopkov čiščenja vode na naravo ostankov, prisotnih v pitni vodi,
the endocrine disrupting potential of fenpicoxamid as regards the thyroid modality/pathway, providing in particular mechanistic data to clarify according to Points 3.6.5 and 3.8.2 of Annex II of Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605, whether the effects observed in the studies submitted for approval are or are not related to a thyroid endocrine disrupting mode of action.
lastnostih fenpikoksamida kot potencialnega endokrinega motilca ščitničnega delovanja, s predložitvijo zlasti podatkov o mehanizmu delovanja, s katerimi se v skladu s točkama 3.6.5 in 3.8.2 Priloge II k Uredbi (ES) št. 1107/2009, kakor je bila spremenjena z Uredbo Komisije (EU) 2018/605 , pojasni, ali učinki, ugotovljeni v študijah, predloženih v odobritev, povzročajo motnje delovanja ščitnice.
The applicant shall submit to the Commission, the Member States and the Authority the information referred to in point 1 by 11 October 2019, in point 2 within 2 years of a guidance document on evaluation of the effect of water treatment processes on the nature of residues present in surface and groundwater being made public by the Commission and in point 3 by 10 November 2020.
Vlagatelj Komisiji, državam članicam in Agenciji predloži informacije iz točke 1 do 11. oktobra 2019, informacije iz točke 2 v dveh letih po tem, ko Komisija objavi smernice za oceno učinka postopkov čiščenja vode na naravo ostankov, prisotnih v površinski in podzemni vodi, informacije iz točke 3 pa do 10. novembra 2020.
Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties (OJ L 101, 20.4.2018, p. 33).
Uredba Komisije (EU) 2018/605 z dne 19. aprila 2018 o spremembi Priloge II k Uredbi (ES) št. 1107/2009 z določitvijo znanstvenih meril za ugotavljanje lastnosti endokrinih motilcev (UL L 101, 20.4.2018, str. 33).
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on fenpicoxamid, and in particular Appendices I and II thereto, shall be taken into account.
Za izvajanje enotnih načel iz člena 29(6) Uredbe (ES) št. 1107/2009 se upoštevajo ugotovitve iz poročila o pregledu snovi fenpikoksamid ter zlasti dodatkov I in II k poročilu.
The applicant shall submit to the Commission, the Member States and the Authority the information referred to in point 1 by 11 October 2019, in point 2 within 2 years of a guidance document on evaluation of the effect of water treatment processes on the nature of residues present in surface and groundwater being made public by the Commission and in point 3 by 10 November 2020.’
Vlagatelj Komisiji, državam članicam in Agenciji predloži informacije iz točke 1 do 11. oktobra 2019, informacije iz točke 2 v dveh letih po tem, ko Komisija objavi smernice za oceno učinka postopkov čiščenja vode na naravo ostankov, prisotnih v površinski in podzemni vodi, informacije iz točke 3 pa do 10. novembra 2020.“
(OJ L 101, 20.4.2018, p. 33).
EFSA (Evropska agencija za varnost hrane), 2018.
Commission Implementing Regulation (EU) 2018/1266
Izvedbena uredba Komisije (EU) 2018/1266
amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metaldehyde, paclobutrazol, pencycuron, sintofen, tau-fluvalinate and tebufenozide
o spremembi Izvedbene uredbe (EU) št. 540/2011 glede podaljšanja obdobij odobritve za aktivne snovi 1-dekanol, 6-benziladenin, aluminijev sulfat, apneno žveplo, azadirahtin, bupirimat, cikloksidim, dazomet, diklofop, ditianon, dodin, fenazakvin, fluometuron, flutriafol, heksitiazoks, himeksazol, indolilmaslena kislina, isoksaben, karboksin, kletodim, metaldehid, paklobutrazol, pencikuron, sintofen, tau-fluvalinat in tebufenozid
Applications for the renewal of the approval of 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metaldehyde, paclobutrazol, pencycuron, sintofen, tau-fluvalinate and tebufenozide were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012.
V skladu z Izvedbeno uredbo Komisije (EU) št. 844/2012 so bili vloženi zahtevki za obnovitev odobritve snovi 1-dekanol, 6-benziladenin, aluminijev sulfat, apneno žveplo, azadirahtin, bupirimat, cikloksidim, dazomet, diklofop, ditianon, dodin, fenazakvin, fluometuron, flutriafol, heksitiazoks, himeksazol, indolilmaslena kislina, isoksaben, karboksin, kletodim, metaldehid, paklobutrazol, pencikuron, sintofen, tau-fluvalinat in tebufenozid.
In view of the time and resources necessary for completing the assessment of applications for renewal of approval of a large number of active substances the approvals of which are expiring between 2019 and 2021, Commission Implementing Decision C(2016) 6104 established a work programme grouping together similar active substances and setting priorities on the basis of safety concerns for human and animal health or the environment as provided for in Article 18 of Regulation (EC) No 1107/2009.
Ob upoštevanju časa in virov, ki so potrebni za dokončanje ocene zahtevkov za obnovitev odobritve velikega števila aktivnih snovi, ki jim bo odobritev potekla med letoma 2019 in 2021, je bil z Izvedbenim sklepom Komisije C(2016) 6104 oblikovan delovni program, ki združuje podobne aktivne snovi in določa prednostne naloge na podlagi skrbi za varovanje zdravja ljudi in živali ali okolja, kot je določeno v členu 18 Uredbe (ES) št. 1107/2009.
As the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metaldehyde, paclobutrazol, pencycuron, sintofen, tau-fluvalinate and tebufenozide do not fall in the prioritised categories of Implementing Decision C(2016) 6104, their approval period should be extended by either two or three years, taking into account the current date of expiry, the fact that in accordance with Article 6(3) of Implementing Regulation (EU) No 844/2012 the supplementary dossier for an active substance is to be submitted no later than 30 months before expiry of the approval, the need to ensure a balanced distribution of responsibilities and work among Member States acting as rapporteurs and co-rapporteurs and the available resources necessary for assessment and decision-making.
Ker aktivne snovi 1-dekanol, 6-benziladenin, aluminijev sulfat, apneno žveplo, azadirahtin, bupirimat, cikloksidim, dazomet, diklofop, ditianon, dodin, fenazakvin, fluometuron, flutriafol, heksitiazoks, himeksazol, indolilmaslena kislina, isoksaben, karboksin, kletodim, metaldehid, paklobutrazol, pencikuron, sintofen, tau-fluvalinat in tebufenozid ne spadajo v prednostne kategorije iz Izvedbenega sklepa C(2016) 6104, bi bilo treba njihova obdobja odobritve podaljšati za dve ali tri leta, ob upoštevanju sedanjega datuma poteka veljavnosti, dejstva, da je treba v skladu s členom 6(3) Izvedbene uredbe (EU) št. 844/2012 dopolnilno dokumentacijo za aktivno snov predložiti najpozneje 30 mesecev pred potekom odobritve, nujnosti zagotovitve uravnotežene razdelitve odgovornosti in nalog med državami članicami poročevalkami in soporočevalkami ter razpoložljivih virov, potrebnih za ocenjevanje in odločanje.
It is therefore appropriate to extend the approval period for the active substances carboxin, clethodim, cycloxydim, dazomet, diclofop, fenazaquin, hymexazol, indolylbutyric acid, metaldehyde, and paclobutrazol by two years, and the approval period of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, dithianon, dodine, fluometuron, flutriafol, hexythiazox, isoxaben, lime sulphur, pencycuron, sintofen, tau-fluvalinate and tebufenozide by three years.
Zato je primerno obdobja odobritve za aktivne snovi cikloksidim, dazomet, diklofop, fenazakvin, himeksazol, indolilmaslena kislina, karboksin, kletodim, metaldehid in paklobutrazol podaljšati za dve leti, obdobja odobritve za aktivne snovi 1-dekanol, 6-benziladenin, aluminijev sulfat, apneno žveplo, azadirahtin, bupirimat, ditianon, dodin, fluometuron, flutriafol, heksitiazoks, isoksaben, pencikuron, sintofen, tau-fluvalinat in tebufenozid pa za tri leta.
Where no supplementary dossier in accordance with Implementing Regulation (EU) No 844/2012 is submitted no later than 30 months before the respective expiry date laid down in the Annex to this Regulation, the expiry date should remain the same as before this Regulation or it should be set at the earliest date thereafter.
Če dopolnilna dokumentacija v skladu z Izvedbeno uredbo (EU) št. 844/2012 ni bila predložena najpozneje 30 mesecev pred ustreznim datumom poteka veljavnosti iz Priloge k tej uredbi, bi moral datum poteka veljavnosti ostati enak kot pred to uredbo ali pa bi ga bilo treba določiti čim prej po tem datumu.
Where the Commission will adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission will set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later.
Kadar Komisija sprejme uredbo, ki določa, da se odobritev aktivne snovi iz Priloge k tej uredbi ne obnovi, ker merila za odobritev niso izpolnjena, Komisija določi isti datum poteka veljavnosti kot pred to uredbo ali datum začetka veljavnosti Uredbe, ki določa, da se odobritev aktivne snovi ne obnovi, odvisno od tega, kateri datum je poznejši.
in the sixth column, expiration of approval, of row 316, Cycloxydim, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 316 se za cikloksidim datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 317, 6-Benzyladenine, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 317 se za 6-benziladenin datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 322, Hymexazol, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 322 se za himeksazol datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 323, Dodine, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 323 se za dodin datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 326, Indolylbutyric acid, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 326 se za indolilmasleno kislino datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 328, Tau-fluvalinate, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 328 se za tau-fluvalinat datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 329, Clethodim, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 329 se za kletodim datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 330, Bupirimate, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 330 se za bupirimat datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 333, 1-decanol, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 333 se za 1-dekanol datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 334, Isoxaben, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 334 se za isoksaben datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 335, Fluometuron, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 335 se za fluometuron datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 337, Carboxin, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 337 se za karboksin datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 339, Dazomet, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 339 se za dazomet datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 340, Metaldehyde, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 340 se za metaldehid datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 341, Sintofen, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 341 se za sintofen datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 342, Fenazaquin, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 342 se za fenazakvin datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 343, Azadirachtin, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 343 se za azadirahtin datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 344, Diclofop, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 344 se za diklofop datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 345, Lime sulphur, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 345 se za apneno žveplo datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 346, Aluminium sulfate, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 346 se za aluminijev sulfat datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 348, Paclobutrazol, the date is replaced by ‘31 May 2023’;
v šestem stolpcu vrstice 348 se za paklobutrazol datum veljavnosti registracije nadomesti z „31. maj 2023“;
in the sixth column, expiration of approval, of row 349, Pencycuron, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 349 se za pencikuron datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 350, Tebufenozide, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 350 se za tebufenozid datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 351, Dithianon, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 351 se za ditianon datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 352, Hexythiazox, the date is replaced by ‘31 May 2024’;
v šestem stolpcu vrstice 352 se za heksitiazoks datum veljavnosti registracije nadomesti z „31. maj 2024“;
in the sixth column, expiration of approval, of row 353, Flutriafol, the date is replaced by ‘31 May 2024’.
v šestem stolpcu vrstice 353 se za flutriafol datum veljavnosti registracije nadomesti z „31. maj 2024“.
Commission Implementing Regulation (EU) 2018/1267
Izvedbena uredba Komisije (EU) 2018/1267
on the minimum selling price for skimmed milk powder for the 24th partial invitation to tender within the tendering procedure opened by Implementing Regulation (EU) 2016/2080
o določitvi najnižje prodajne cene za posneto mleko v prahu za štiriindvajseti delni razpis v okviru razpisnega postopka, odprtega z Izvedbeno uredbo (EU) 2016/2080
Commission Implementing Regulation (EU) 2016/2080 has opened the sale of skimmed milk powder by a tendering procedure.
Z Izvedbeno uredbo Komisije (EU) 2016/2080 se je začela prodaja posnetega mleka v prahu z razpisnim postopkom.
In the light of the tenders received for the 24th partial invitation to tender, a minimum selling price should be fixed.
Glede na ponudbe, predložene za štiriindvajseti delni razpis, je treba določiti najnižjo prodajno ceno.
For the 24th partial invitation to tender for the selling of skimmed milk powder within the tendering procedure opened by Implementing Regulation (EU) 2016/2080, in respect of which the period during which tenders were to be submitted ended on 18 September 2018, the minimum selling price shall be 123 EUR/100 kg.
Za štiriindvajseti delni razpis za prodajo posnetega mleka v prahu v okviru razpisnega postopka, odprtega z Izvedbeno uredbo (EU) 2016/2080, katerega rok za predložitev ponudb je potekel 18. septembra 2018, znaša najnižja prodajna cena 123 EUR/100 kg.
Commission Implementing Regulation (EU) 2016/2080 of 25 November 2016 opening the sale of skimmed milk powder by a tendering procedure (OJ L 321, 29.11.2016, p. 45).
Izvedbena uredba Komisije (EU) 2016/2080 z dne 25. novembra 2016 o začetku prodaje posnetega mleka v prahu z razpisnim postopkom (UL L 321, 29.11.2016, str. 45).
Council Regulation (EU) 2018/1277
Uredba Sveta (EU) 2018/1277
on fixing the export refunds on poultrymeat
o določitvi izvoznih nadomestil za perutninsko meso
Under Council Regulation (EC) No 1234/2007, which was repealed by Regulation (EU) No 1308/2013 of the European Parliament and of the Council, the Commission was empowered to fix refunds when considered necessary in accordance with the criteria and requirements established in Regulation (EC) No 1234/2007.
V Uredbi Sveta (ES) št. 1234/2007, ki je bila razveljavljena z Uredbo (EU) št. 1308/2013 Evropskega parlamenta in Sveta, je bila Komisija pooblaščena za določitev nadomestil, kadar je to potrebno v skladu z merili in zahtevami iz Uredbe (ES) št. 1234/2007.
Against this background, Commission Implementing Regulation (EU) No 689/2013 was adopted.
Na tej podlagi je bila sprejeta Izvedbena uredba Komisije (EU) št. 689/2013.
By its judgment of 20 September 2017, the Court of Justice annulled Implementing Regulation (EU) No 689/2013.
Sodišče je s sodbo z dne 20. septembra 2017 Izvedbeno uredbo (EU) št. 689/2013 razglasilo za nično.
The Court of Justice held that the failure to comply with the procedural rules relating to the adoption of an act adversely affecting a person constitutes an infringement of an essential procedural requirement and that, therefore, the act vitiated by such a defect must be annulled.
Sodišče je navedlo, da nespoštovanje postopkovnih pravil v zvezi s sprejetjem akta, ki posega v položaj, pomeni bistveno kršitev postopka in je zato treba akt, pri katerem je taka kršitev podana, razglasiti za ničen.
The Court of Justice also ruled that notwithstanding the breach of essential procedural requirements, no error had been disclosed affecting the conformity of the act, which contained the measures necessary for the implementation of Regulation (EC) No 1234/2007.
Sodišče je razsodilo tudi, da ne glede na kršitev osnovnih postopkovnih zahtev ni bilo ugotovljene nobene napake, ki bi vplivala na skladnost akta, v katerem so potrebni ukrepi za izvajanje Uredbe (ES) št. 1234/2007.
Thus, for the sake of legal certainty and to avoid adversely affecting the implementation of Regulation (EC) No 1234/2007, it held that the effects of the contested Regulation be maintained until the entry into force of a new act intended to replace it.
Zato je zaradi pravne varnosti in v izogib negativnemu vplivu na izvajanje Uredbe (ES) št. 1234/2007 odločilo, da se učinki sporne uredbe ohranijo do začetka veljavnosti novega akta, ki jo bo nadomestil.
Regulation (EU) No 1308/2013 repealed the procedural provisions of Regulation (EC) No 1234/2007 concerning the adoption of acts fixing refunds.
Uredba (EU) št. 1308/2013 je razveljavila postopkovne določbe Uredbe (ES) št. 1234/2007 glede sprejetja aktov o določitvi nadomestil.
Regulation (EU) No 1308/2013 applies since 1 January 2014.
Uredba (EU) št. 1308/2013 se uporablja od 1. januarja 2014.
It is therefore necessary to fix the export refunds on poultrymeat at the same level as they were fixed by Implementing Regulation (EU) No 689/2013, in order to comply with the judgment of the Court of Justice.
Zato je treba določiti izvozna nadomestila za perutninsko meso na isto raven, kot so bila določena v Izvedbeni uredbi (EU) št. 689/2013, da se upošteva sodba Sodišča.